ACE2 and COVID-19: Based on previous histopathological reports of vasculopathy in COVID-19 and higher ACE-2 expression in cells of the blood–brain barrier, we hypothesized that post-SARS-CoV-2 individuals would show alterations in imaging markers of small vessel disease burden (14).